Cafa, that SRX analysis was an interesting post in the ASX...

First 12 Last

Share
Profile

Follow
JCoure

12,929 Posts.

132

24/03/17

17:25

Post #: 23610663
Share

Originally posted by cafa ↑

Thanks pal.
I'll try and lay it out as best I can.

The company in Q is SRX. They have just announced the top line results of a clinical trail and are due to present at ASCO in 10 days time.

The progession free survivcal of cancer in the liver was a 64% improvemnt with a P value of .002. This suggests the trial was overpowered by a considerable amout. There were just under 600 on the trail, about 50/50 to the control arm. This was a secondary end point, so there is no ethical aspect of an overpowered trial!

SRX have stated that to yield a statistically significant value for overall survival (the big game in town) they need to combine the data with two other trials where the data will not be avilable until later in 2016, for a total trial population of about 1000, 50/50 to control arm. This is based on an 80% power.

My undersatnding is that a P value of 0.05 is the go for clinical trails (less than 5% chance of the result being a random event), and that an 80% power should bring the P value down to about 0.01.

The value we have been given is that they are looking for about an additional 3 months OS

So the big question in my head is this. If for instance the OS from the current trial was say in excess of 6 months, would this yield a P value of about 0.01 for a 3 month advantage, or am I mixing apples and pears?

If the OS was in excess of 6months what P value could be concluded with only 60% of the expected population data available.

If there is any other info that would assist please shout.

And if I really am barking up te wrong tree, then apologies for wasting your time :-(

Cheers
CAFA

Expand

Cafa, that SRX analysis was an interesting post in the ASX forum.

In hindsight, given what happened and what will happen with the SRX trials, ASX must be happy that SRX has stayed on the ASX.

The amount of SRX volatility volume is worth a fair bit of crust to ASX.

ASX Price at posting: $49.67 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

ENV

Anteris Tech eyes US market liquidity with early-stage NASDAQ IPO paperwork

There are more pages in this discussion • 3 more messages in this thread...

First 12 Last

Cafa, that SRX analysis was an interesting post in the ASX...

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Anteris Tech eyes US market liquidity with early-stage NASDAQ IPO paperwork

Featured News

Featured News

Cafa, that SRX analysis was an interesting post in the ASX...

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Anteris Tech eyes US market liquidity with early-stage NASDAQ IPO paperwork

Featured News

Featured News